Abbott Labs hasn't had the best luck this year as far as deals go, but it seems to have gotten some of its M&A mojo back with its latest transaction.
The $62 billion medical-device company announced late Friday that it's selling its eye-surgery equipment unit, Abbott Medical Optics, to Johnson & Johnson for $4.33 billion. Unlike its planned takeovers of St. Jude and Alere -- which have been questioned from a strategic standpoint and ran into some nettlesome issues, from accusations of cybersecurity risk at the former to accounting missteps at the latter -- there's nothing not to like about this divestiture. It makes sense no matter how you look at it.
The $62 billion medical-device company announced late Friday that it's selling its eye-surgery equipment unit, Abbott Medical Optics, to Johnson & Johnson for $4.33 billion. Unlike its planned takeovers of St. Jude and Alere -- which have been questioned from a strategic standpoint and ran into some nettlesome issues, from accusations of cybersecurity risk at the former to accounting missteps at the latter -- there's nothing not to like about this divestiture. It makes sense no matter how you look at it.
